Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Riemer, Birgit
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy	Recruiting	3	102	Europe, Canada, US, RoW	Ampreloxetine, TD-9855, Placebo	Theravance Biopharma	Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy	12/24	01/27
Becker, Jefferson
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy	Recruiting	3	102	Europe, Canada, US, RoW	Ampreloxetine, TD-9855, Placebo	Theravance Biopharma	Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy	12/24	01/27
Hamzeh, Rasha
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy	Recruiting	3	102	Europe, Canada, US, RoW	Ampreloxetine, TD-9855, Placebo	Theravance Biopharma	Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy	12/24	01/27
POST 9, NCT05657925: Study of Ondansetron in the Prevention of Sleep Syncope: The Nineth Prevention of Syncope Trial (POST9)	Not yet recruiting	3	24	Canada	ondansetron 8 mg, Matching placebo	University of Calgary	Sleep Syncope	12/26	12/27
CO2-nOH, NCT06751888: Controlled CO2 Inhalation in NOH	Not yet recruiting	N/A	28	Canada	Controlled CO2 delivery, Controlled CO2 delivery (Sham)	University of Calgary	Neurogenic Orthostatic Hypotension	12/28	12/28